FindTrial
Sign In

The clinical significance of research in the discordance between FISH and IHC(1+/-) or IHC (3+) in the judgment of HER-2 in breast cancer

The clinical significance of research in the discordance between FISH and IHC(1+/-) or IHC (3+) in the judgment of HER-2 in breast cancer

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-15007250
Enrollment
Unknown
Registered
2015-10-09
Start date
2015-10-17
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

IHC (1+/-):non
IHC (3+):non

Sponsors

Department of Endocrine and Breast Surgery of the First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: every one in this research must satisfy 3 conditions at the same time: 1. Pathological diagnosed as breast cancer in the First Affiliated Hospital of Chongqing Medical University; 2. IHC (1+/-) or IHC (3+); 3. the patients consent to screening and signed informed consent form.

Exclusion criteria

Exclusion criteria: The amount of isolated tissue of the patient who has breast cancer is not enough to perform the immunohistochemical test or FISH

Design outcomes

Primary

MeasureTime frame
status of HER-2 gene;—

Countries

China

Contacts

Public ContactLingquan Kong
huihuikp@163.com+86 13101380893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026